Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Clarity Pharmaceuticals announced preliminary SECuRE trial results showing 74% of participants achieved PSA25 and 81% disease control with 8 GBq 67Cu-SAR-bisPSMA. A 76-year-old patient achieved undetectable disease after two cycles, and shares rose 14%.
Magnesium supplements can interact with antibiotics and bone-loss drugs, reducing their effectiveness. High doses may cause diarrhea, nausea, and low blood pressure. Experts advise talking to a health care provider before use.
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
FDA approved Novartis' Fabhalta for IgAN to slow kidney function decline. Phase III ALIGN data for Vanrafia showed ~34% slower eGFR decline vs placebo and were published in The Lancet.
FDA granted traditional approval to Novartis' Fabhalta (iptacopan) for IgA nephropathy. Phase 3 APPLAUSE-IgAN data showed eGFR decline slowed by 48% versus placebo over two years.
FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive cholangiocarcinoma on May 8, 2026. The eNRGy trial showed a 36.8% ORR. It also received priority review, breakthrough, and orphan designations.
The FDA approved pivekimab sunirine-pvzy (Decnupaz) for adults with BPDCN on May 27, 2026, based on CADENZA trial data showing a 69.7% CR/CRc rate in treatment-naïve patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07770295 |
Effects of Foot Reflexology on Postoperative Pain, Anxiety, Nausea, and Vomiting Among Patients After Laparoscopic Cholecystectomy |
COMPLETED | NA |
| NCT07738744 |
A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Liver and Digestive Health |
COMPLETED | NA |
| NCT07523230 |
Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department |
COMPLETED | NA |
| NCT07378839 |
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting |
RECRUITING | NA |
| NCT07328477 |
Box Breathing for Anxiety, Pain and Nausea in ERCP Patients |
COMPLETED | NA |
| NCT07208305 |
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting |
RECRUITING | PHASE3 |
| NCT07179094 |
The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash |
NOT_YET_RECRUITING | NA |
| NCT07169851 |
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer |
RECRUITING | PHASE2 |
| NCT07140341 |
A Clinical Study to Assess the Effectiveness of ENO Lime in Participants With Ajeerna Vyadhi (Acidity, Acid Indigestion, Indigestion, and Associated Nausea) |
COMPLETED | PHASE3 |
| NCT07069023 |
Tiredness and Nausea and Vomiting Management in Oncology Patients |
COMPLETED | NA |
